Investigational Drug Information for Brensocatib
✉ Email this page to a colleague
What is the drug development status for Brensocatib?
Brensocatib is an investigational drug.
There have been 11 clinical trials for Brensocatib.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 5th 2020.
The most common disease conditions in clinical trials are Fibrosis, Polyps, and Bronchiectasis. The leading clinical trial sponsors are Insmed Incorporated, NHS Tayside, and University of Dundee.
There are four US patents protecting this investigational drug and sixty-five international patents.
Summary for Brensocatib
| US Patents | 4 |
| International Patents | 65 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2020-06-05) |
| Vendors | 33 |
Recent Clinical Trials for Brensocatib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants | Insmed Incorporated | Phase 1 |
| A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Insmed Incorporated | Phase 2 |
| A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants | Insmed Incorporated | Phase 1 |
Clinical Trial Summary for Brensocatib
Top disease conditions for Brensocatib
Top clinical trial sponsors for Brensocatib
US Patents for Brensocatib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Brensocatib | ⤷ Sign Up | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Sign Up |
| Brensocatib | ⤷ Sign Up | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Sign Up |
| Brensocatib | ⤷ Sign Up | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| Brensocatib | ⤷ Sign Up | Certain (25)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Brensocatib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Brensocatib | Argentina | AR099177 | 2034-01-24 | ⤷ Sign Up |
| Brensocatib | Australia | AU2015208932 | 2034-01-24 | ⤷ Sign Up |
| Brensocatib | Australia | AU2017200338 | 2034-01-24 | ⤷ Sign Up |
| Brensocatib | Australia | AU2018202956 | 2034-01-24 | ⤷ Sign Up |
| Brensocatib | Australia | AU2019202675 | 2034-01-24 | ⤷ Sign Up |
| Brensocatib | Canada | CA2935625 | 2034-01-24 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
